Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Lisheng Pharmaceutical, plans to establish a fund with several partners, aiming to raise a total of RMB 500 million, with Lisheng contributing RMB 174 million, representing 34.75% of the total fund [1] Group 1: Fund Establishment - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), has a proposed duration of five years [1] - The fund will primarily invest in the health and biotechnology sectors in China [1] Group 2: Strategic Implications - The potential transaction, if realized, is expected to enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [1] - The group's investment in the fund is anticipated to provide more industry acquisition opportunities aligned with its development strategy and offer potential returns exceeding fixed income, thereby improving capital allocation efficiency and enhancing capital returns [1]

Group 1 - Company Tianjin Development (00882.HK) announced its indirect subsidiary, Lisheng Pharmaceutical (002393.SZ), plans to establish a fund with several partners, with a proposed total subscription amount of RMB 500 million [1] - Lisheng Pharmaceutical intends to contribute RMB 173.75 million, representing 34.75% of the total proposed subscription amount for the fund [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), aims to invest in the health and biotechnology sectors in China [1] Group 2 - The board believes that the potential transaction will enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [2] - The group's investment in the fund is expected to provide more industry acquisition opportunities aligned with its development strategy and offer potential returns exceeding fixed income, thereby improving capital allocation efficiency and returns [2]

Group 1 - The company Tianjin Development (00882.HK) announced its indirect subsidiary, Lisheng Pharmaceutical (002393.SZ), plans to establish a fund with a total proposed subscription amount of RMB 500 million, with Lisheng contributing RMB 173.75 million, accounting for 34.75% of the total [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), has a proposed duration of five years and will primarily invest in the health and biotechnology sectors in China [1] - The establishment of this fund is expected to deepen the company's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [2] Group 2 - The company believes that investing in the fund will provide more industry acquisition opportunities aligned with its development strategy and offer potential returns beyond fixed income, thereby improving capital allocation efficiency and enhancing capital returns [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號： 882） 潛在須予披露及關連交易 設立基金 董事會宣佈，力生製藥（本公司間接非全資附屬公司）擬與建信股權、泰達 私募、共青城建興、泰達國際、國資母基金及戰新基金就設立基金訂立合夥 協議，該基金的建議認繳出資總額為人民幣500,000,000元（相當於約港幣 547,045,952元），其中，力生製藥擬向該基金認繳出資人民幣173,750,000元 （相當於約港幣190,098,468元），佔該基金建議認繳出資總額的34.75%，惟 須受合夥協議的條款及條件所規限。 由於根據上市規則第14.07條計算有關潛在交易的最高適用百分比率超過 5%，但概無適用百分比率超過25%，故潛在交易（倘落實）將構成本公司 的一項須予披露交易，並須遵守上市規則第14章項下的申報及公告規定。 於本公告日期，泰達控股透過其若干附屬公司（包括渤海國資）間接持有已 發行股份總數約62.81 ...

Group 1 - The company Tianjin Development (00882.HK) announced that it will hold a board meeting on August 28, 2025, to approve the release of its interim results for the six months ending June 30, 2025 [1] - The board meeting will also consider the distribution of an interim dividend, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） 董事會召開日期 天津發展控股有限公司（「 本公司 」）董事會（「 董事會 」）謹此 宣佈，本公司將於二零二五年八月二 十八日（星期四）舉行董事會 會議，藉以（其中包括）批准 發佈本公司及其附屬公司截至 二零二五年六月三十日止六個月之中 期業績公告，以及考慮派發中 期股息（如有）。 承董事會命 天津發展控股有限公司 主席及執行董事 滕 飛 香港，二零二五年八月十八日 於本公告日期，本公司董事會包括滕飛先生、翟欣翔博士、夏濱輝先生、 孫利軍先生 * 、伍綺琴女士 ** 、黃紹開先生 ** 、樓家強先生 ** 及 冼漢廸先生 ** 。 * 非執行董事 ** 獨立非執行董事 （股份代號： 882） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 天津發展控股有限公司 | | | 呈交日期: | 2025年8月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00882 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,072,770,125 | | 0 | | 1,072,770,125 | | 增加 / 減少 ...

Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical (002393), has entered into several wealth management agreements with Industrial Bank, totaling a principal amount of RMB 185 million (approximately HKD 201 million) for investment products [1] Group 1 - On March 31, 2025, Lifescience Pharmaceutical entered into its first wealth management agreement with Industrial Bank, with a principal amount of RMB 20 million (approximately HKD 21.74 million) for structured deposits [2] - On May 7, 2025, Lifescience Pharmaceutical signed its second wealth management agreement with Industrial Bank and Xinyin Wealth Management, with a principal amount of RMB 10 million (approximately HKD 10.87 million) for fixed income investment products [2] - On May 7, 2025, Lifescience Pharmaceutical entered into its third wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 7, 2025, Lifescience Pharmaceutical signed its fourth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 29, 2025, Lifescience Pharmaceutical entered into its fifth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 35 million (approximately HKD 38.04 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its sixth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 50 million (approximately HKD 54.35 million) [2] - On June 11, 2025, Lifescience Pharmaceutical entered into its seventh wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its eighth wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 40 million (approximately HKD 43.48 million) [2]

Group 1 - A batch of non-road mining dump trucks produced by Inner Mongolia North Heavy Industries Group Co., Ltd. has completed export leasing procedures at Tianjin Dongjiang Customs and is being shipped overseas from Tianjin Port [1] - Tianjin Dongjiang Customs has established a rapid customs clearance mechanism, completing the customs procedures in just one day by providing guidance on various business processes [1] - The leasing trade, as an important part of emerging trade formats, allows domestic companies to expand international markets and reduce financial pressure on lessees, with Tianjin's leasing trade import and export volume reaching 14.58 billion yuan, a year-on-year increase of 247.9% [1] Group 2 - Financial institutions in Tianjin, such as Agricultural Bank of China Tianjin Branch, are actively supporting the development of leasing trade, with a leasing business balance exceeding 18 billion yuan and new investments of over 5.5 billion yuan this year [2] - The bonded leasing model in Tianjin has been promoted to other regions like Shanghai, Guangzhou, and Chongqing, forming an annual bonded leasing industry worth hundreds of billions [2] - In 2024, Tianjin Customs' bonded leasing model was selected as one of the first pilot projects for the "Smart Customs Strong Country" initiative by the General Administration of Customs [2]

Financial Performance - The consolidated profit attributable to shareholders for the year ended December 31, 2024, is approximately HKD 548.1 million, down from HKD 635.6 million in the previous year, representing a decrease of 13.8%[22] - Total revenue for 2024 is HKD 3,359 million, a slight increase of 0.6% compared to HKD 3,338 million in 2023[20] - The utility segment reported revenue of HKD 1,444 million, a decrease of 9.8% from HKD 1,600 million in 2023[20] - The pharmaceutical segment achieved revenue of HKD 1,609 million, an increase of 11.7% from HKD 1,441 million in 2023[20] - The company’s mechanical and electrical segment reported a loss of HKD 104 million, compared to a loss of HKD 29 million in the previous year, indicating a significant decline in performance[21] - The revenue from the thermal energy segment decreased by 11.6% to approximately HKD 1,139,400,000, with profit dropping to about HKD 24,700,000[37] - The electricity segment's revenue was approximately HKD 2,399,400,000, a decrease of 4.2%, contributing a profit of about HKD 57,500,000[38] - The profit from the pharmaceutical segment was approximately HKD 443,300,000, compared to HKD 370,100,000 last year, with a comparable profit of approximately HKD 105,000,000 for 2023 after excluding one-time impacts[40] Dividends and Shareholder Returns - The board has proposed a final dividend of HKD 0.0882 per share, bringing the total dividend for the year to HKD 0.14 per share, an increase of 14.3% from the previous year[22] - The board proposed a final dividend of HKD 0.0882 per share for the year ending December 31, 2024, compared to HKD 0.0880 per share in 2023, resulting in a total annual dividend of HKD 0.14 per share, up from HKD 0.1225 in 2023[61] Strategic Focus and Development - The company plans to focus on steady development of existing businesses and pursue high-quality growth through mergers and acquisitions and restructuring[23] - The company will also concentrate on businesses with development potential and sustainable expansion[23] - The company remains optimistic about future growth despite external uncertainties, emphasizing a commitment to prudent financial management and business integration[29] - The company is committed to leveraging its leadership's diverse expertise to drive growth and innovation in its operations[70] Acquisitions and Investments - The acquisition of a 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. was completed, enhancing the production platform for traditional Chinese medicine[24] - The group completed the acquisition of 65% of Qingchun Kangyuan on February 1, 2024, with a performance commitment ensuring audited net profit of no less than RMB 11,332,200 for the fiscal year 2023[41] Employee and Management Changes - Dr. Zhai Xinxiang appointed as Executive Director and General Manager on September 29, 2023, bringing extensive experience in economic and corporate management[65] - Mr. Xia Binhui appointed as Executive Director and Deputy General Manager on December 30, 2024, with a strong background in asset management and corporate restructuring[66] - Mr. Sun Lijun, a senior accountant, serves as the financial director, bringing rich experience in financial management and capital management[67] - The group employed approximately 2,729 employees as of December 31, 2024, an increase from 2,376 in 2023, including 259 management and 894 technical personnel[58] Environmental, Social, and Governance (ESG) Practices - The company has a strong focus on environmental, social, and governance (ESG) practices, adhering to the Hong Kong Stock Exchange's guidelines for ESG reporting[76] - The ESG report covers the period from January 1, 2024, to December 31, 2024, focusing on key operational categories such as public utilities, pharmaceuticals, and electromechanical sectors[77] - The company emphasizes the importance of sustainability in its daily operations and has established a governance framework for implementing various ESG policies and initiatives[80] - The company aims to provide balanced and fair information regarding its ESG performance, avoiding misleading presentations[81] Risk Management - The company has established a clear risk management framework to identify, assess, and manage significant risks, including ESG and climate-related risks[86] - The board is committed to maintaining an effective risk management system, with annual reviews to assess its effectiveness[86] - The company has engaged external consultants for regular independent reviews of its risk management and internal control systems[84] Community Engagement and Social Responsibility - Community investment initiatives include volunteer activities and donations to support vulnerable groups, enhancing social responsibility efforts[165] - The company organized various social activities, including providing safe and reliable water supply services to disabled elderly individuals, demonstrating its commitment to community welfare[165] Corporate Governance - The board consists of eight members, including three executive directors and four independent non-executive directors, ensuring a diverse professional background[172] - The company has maintained compliance with the corporate governance code throughout the year, reflecting its commitment to high governance standards[167] - The board has conducted an annual review of the independence of all independent non-executive directors, confirming their compliance with independence criteria[173] Training and Development - The company provided training for 2,158 employees, totaling 68,894 hours in fiscal year 2024, a decrease from 83,225 hours for 1,926 employees in fiscal year 2023[153] - The overall training participation rate for fiscal year 2024 was 86.35%, down from 89.04% in fiscal year 2023, with an average training hours per employee of 27.57, compared to 38.48 hours in the previous year[153] Compliance and Ethical Standards - The company has established a zero-tolerance policy towards money laundering and has implemented written policies to manage key operational processes[95] - No significant non-compliance issues related to corruption and money laundering were found during the reporting period, reflecting the company's commitment to ethical business practices[163]